IPROOV
iProov , a leading provider of biometric authentication technology and genuine presence assurance, today announces the launch of its Palm Verifier product at Finovate Europe 2019.
For the very first time, users will be able to use palm verification on any of their personal devices, either as a standalone mode of authentication or as an additional authentication factor, with strong assurance of genuine presence.
The launch provides a new choice for consumers, employees and enterprises, enabling them to select the secure, device-independent biometric they prefer. For example, users can authenticate themselves using Palm Verifier when conducting high value transactions, attempting to access personal information like medical records, using remote ATMs or gaining physical access to unsupervised remote sites.
Users simply hover their palm above their device and Palm Verifier will authenticate them in under 5 seconds. The process is fast, flexible and hygienic and is also exceptionally easy, intuitive and inclusive to use.
For certain users and in a number of cultures, face verification is neither a preferred nor an accessible mode of authentication. For these users, Palm Verifier will deliver an anonymous, easy, yet highly secure authentication experience that can be used in all light conditions. Unlike faces, palm prints are not shared on social media or stored in government records therefore do not provide traceable clues back to the identity of the user. This means for some users; Palm Verifier’s key benefit is its anonymity.
Palm Verifier is protected by the genuine presence assurance capabilities of iProov’s patented Flashmark technology. As recently endorsed by the UK National Physical Laboratory (NPL), iProov’s Flashmark-based one-time biometrics uniquely protect against spoof and replay attacks. Replay attacks, arising from social engineering and malware, are a particular hazard to consumers.
iProov Face Verifier has already been comprehensively proven in field and laboratory tests to be strongly resistant to the full range of spoof attacks, including 3D solid artefacts. Palm Verifier has the same strong Genuine Presence Assurance, whilst awaiting scale testing of solid artefacts which pose a low hazard thanks to the anonymity of palms.
Andrew Bud, Founder and CEO of iProov, said, “Our mission is to create a safe and secure digital environment, in which users feel protected and organisations can trust in the genuine presence of their remote customer.
Palm authentication is an exciting new way to establish trust in digital interaction and support diverse user preferences. Palm Verifier is more than just a great technology innovation, it provides customers with more freedom to choose their method of authentication whilst assuring the genuine presence of their online identity.
-ends-
About iProov
Founded in 2011 by CEO Andrew Bud, iProov is a world leader in spoof-resistant, biometric facial verification technology. Its technology is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine and to guard them against fraudulent attempts to gain access to personal data or use a stolen identity. For more information, please see www.iproov.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190211005582/en/
Contact:
Connor Mitchell Tyto connor.mitchell@tytopr.com +44 203 026 0000
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom